Showing results (41-50 of 112) with videos related to
Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2014
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancerMichael S Gordon, Francisco Robert, Daniela Matei, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2022
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung CancerD Ross Camidge, Fabrice Barlesi, Jonathan W Goldman, et al.Frontiers in Oncology|August 9, 2018
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLCCorey J Langer, Edward S Kim, Eric C Anderson, et al.NPJ Precision Oncology|June 26, 2026
Redefining therapeutic horizons in thymic epithelial tumors: precision, combinations, and emerging biologyJennifer A Marks, Rohan Maniar, Kavitha J Ramchandran, et al.JTO Clinical and Research Reports|June 20, 2022
Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief ReportYuanbin Chen, Luis Paz-Ares, Niels Reinmuth, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 27, 2018
Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLCScott Gettinger, Matthew D Hellmann, Laura Q M Chow, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung CarcinomaD Ross Camidge, Daniel Morgensztern, Rebecca S Heist, et al.Clinical Lung Cancer|January 19, 2025
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket TrialJonathan W Goldman, Alejandro Martinez Bueno, Christophe Dooms, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 30, 2016
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung CancerScott Gettinger, Naiyer A Rizvi, Laura Q Chow, et al.Pageof 12